Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Addex Increases Issued Share Capital to Create Treasury Shares

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Addex Reports Q1 2023 Financial Results and Provides Corporate Update

Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

Addex Convenes Annual General Meeting 2023

Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023

Addex Completes $5.0 Million Equity Financing

Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease